In humans, there are two types of FcγR: the activating receptor, which contains the CD64 (FcγRI), CD32a (FcγRIIA), CD32c (FcγRIIC), CD16a (FcγRIIIA), and CD16b (FcγRIIIB); and the inhibiting receptor, ...

Therapeutic antibodies are now the major class of successful protein drugs with many more in development to target a variety of major diseases. An important and desirable biological activity of most ...

NK cell-related immunotherapeutics, such as tumor-specific monoclonal antibodies (mAbs) to elicit NK cell-mediated ADCC against tumor cells, are being developed for the treatment of cancers. As an ...

Development of an IHC-based detection method for studying indoleamine 2,3-dioxygenase 1 (IDO1) expression in human cancers. Endogenous anti-β-glucan antibodies as a potential predictive biomarker for ...

BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on ...

A phase I dose escalation study of a 2 day lapatinib chemosensitization pulse preceding weekly intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with advanced cancer This ...

BioWorld - Saturday, October 19, 2024 Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards See today's BioWorld Science Home » NNV-024 shows enhanced ADCC in models of B-cell malignancies ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101  BERLIN, Germany and BRUSSELS, Belgium, December 09, 2025 / Biotech ...

Researchers from Nordic Nanovector ASA presented the discovery of a novel humanized anti-CD37 monoclonal antibody, NNV-024, engineered to exhibit a strong antibody-dependent cellular cytotoxicity ...